Equities
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)2.49
  • Today's Change0.01 / 0.40%
  • Shares traded95.22k
  • 1 Year change+28.05%
  • Beta2.3018
Data delayed at least 15 minutes, as of Mar 28 2024 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

  • Revenue in EUR (TTM)22.63m
  • Net income in EUR-54.96m
  • Incorporated2000
  • Employees--
  • Location
    Cellectis SA8, rue de la Croix JarryPARIS 75013FranceFRA
  • Phone+33 181691600
  • Fax+33 181691606
  • Websitehttps://www.cellectis.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Maat Pharma SA2.31m-14.73m102.22m47.00--3.26--44.18-1.39-1.390.22012.700.0487.873.0053,813.95-30.58---38.13--76.19---636.60--4.14-60.840.2931--47.12---52.05------
Ose Immunotherapeutics SA2.23m-23.00m105.79m62.00--4.57--47.50-1.18-1.180.11661.060.0256--3.22---26.46-17.17-33.15-20.55-----1,032.87-94.71---97.810.6659---87.83-38.07-29.52---17.11--
Transgene SA7.63m-22.33m114.97m164.00------15.06-0.22-0.220.0759-------------24.81---29.79-----292.48-193.24---------23.681.5131.94--14.44--
Eurofins-Cerep SA46.17m9.21m116.01m233.0012.591.9310.362.511,826.411,826.419,160.0011,939.290.68141.666.04220,892.0013.6015.1916.0618.9485.5767.3019.9519.725.17112.420.000050.0014.4514.3017.0924.52----
Adocia SA5.73m-20.55m125.25m100.00------21.88-2.36-2.360.6532-1.900.1823--16.7955,048.08-65.43-25.65-341.43-37.22-----358.85-101.110.5924-2.782.81--692.73-10.0869.67---40.08--
DBV Technologies SA4.87m-93.97m128.82m88.00--0.8428--26.46-0.9973-0.99730.05171.580.0209--0.373870,562.52-40.35-64.67-46.22-80.94--91.59-1,929.97-1,345.10----0.0128---15.14-18.452.08---38.41--
AB Science SA777.00k-16.89m129.21m89.00------166.29-0.3561-0.35610.0164-0.38790.02840.3942.507,471.15-61.64-70.81-237.22-316.6388.1691.37-2,173.10-1,225.491.41--135.44---40.39-11.245.86--5.07--
Eurobio Scientific SA128.01m7.91m165.01m304.0021.321.046.771.290.75520.755211.9115.450.48563.754.48948,222.303.0021.703.5328.7945.2850.596.1825.062.704.110.37990.00-17.3829.03-58.81---6.24--
Genfit SA29.75m-34.17m166.45m154.00--2.23--5.59-0.6877-0.68770.59881.500.1381535.2516.86201,027.00-15.86-15.88-19.53-19.0292.8094.23-114.87-120.192.95-9.320.5030---68.9631.11-135.27------
Aelis Farma SA5.55m-5.57m171.69m22.00--9.98--30.92-0.4123-0.41230.41871.300.1405--1.36252,409.10-14.09-30.28-22.24-49.56-----100.29-168.222.41--0.1337---58.03---2,589.20------
Inventiva SA14.01m-80.08m173.02m117.00------12.35-1.90-1.900.3357-0.1820.1564--12.60124,008.90-89.37-40.86-136.45-49.44-----571.45-747.461.37-25.031.28--190.3920.48-9.35--5.56--
Innate Pharma SA51.90m-7.57m176.68m191.00--3.39--3.40-0.0843-0.08430.6170.64370.2648--1.77---3.86-8.83-4.87-12.1165.19---14.59-55.55----0.6408--4.68-8.2786.94--10.50--
Cellectis SA22.63m-54.96m178.52m----1.96--7.89-1.05-1.540.43911.270.0998--40.86---27.15-21.38-34.66-26.37---61.60-272.10-268.89---4.960.5559---33.35-5.27-5.77---14.21--
Sensorion SA0.00-22.06m211.99m50.00--4.32-----0.2063-0.20630.000.17790.00-------51.64-35.12-71.66-46.97------------0.0794------4.94--126.45--
Euroapi SA1.02bn-189.70m265.68m3.45k--0.2862.680.2608-2.01-2.0110.739.770.60861.384.24---11.34---15.93--16.15---18.63--0.65730.93620.1955--3.87---1,164.67------
Data as of Mar 28 2024. Currency figures normalised to Cellectis SA's reporting currency: Euro EUR

Institutional shareholders

4.64%Per cent of shares held by top holders
HolderShares% Held
Baillie Gifford & Co.as of 30 Nov 20231.35m1.88%
Capital Research & Management Co. (World Investors)as of 31 Dec 2023761.00k1.06%
Bessemer Investment Management LLCas of 31 Oct 2023413.60k0.58%
JPMorgan Asset Management (UK) Ltd.as of 31 Dec 2022347.50k0.48%
KBC Fund Management Ltd.as of 30 Jun 2023163.45k0.23%
Financi�re Arbevel SAas of 31 Dec 2021135.00k0.19%
Arrowstreet Capital LPas of 30 Jun 202371.64k0.10%
Wellington Management Co. LLPas of 31 Oct 202360.98k0.09%
BG Fund Management Luxembourg SAas of 30 Jun 202318.90k0.03%
Perinvest (UK) Ltd.as of 29 Sep 202310.29k0.01%
More ▼
Data from 31 Dec 2023 - 29 Feb 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.